Pharmaceuticals, Biotechnology and Life Sciences
Galapagos NV announced on Tuesday three new Phase 2 Proof-of-Concept studies investigating filgotinib in Sjögren`s syndrome, ankylosing spondylitis, and psoriatic arthritis.
The European Commission (EC) has approved Novartis’ Cosentyx (secukinumab) for the treatment of people living with ankylosing spondylitis (AS) and psoriatic arthritis (PsA). For AS.
Eli Lilly and Company has announced that psoriatic arthritis (PsA) patients treated with ixekizumab for 24 weeks achieved significant improvements…
Novartis has announced new results for Cosentyx (secukinumab) showing no further progression in joint damage in 84% of patients with…
Novartis has announced that the Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Cosentyx(TM) (secukinumab)…
Novartis announced on Wednesday that results from the pivotal Phase III FUTURE 1 study for Secukinumab in psoriatic arthritis (PsA)…